Activation of central 5-hydroxytryptamine 1A receptors powerfully inhibits stress-evoked cardiovascular responses mediated by the dorsomedial hypothalamus, as well as responses evoked by direct activation of neurons within the dorsomedial hypothalamus. The hypothalamic paraventricular nucleus also has a crucial role in cardiovascular regulation, and is believed to regulate heart rate and renal sympathetic activity via pathways that are independent of the dorsomedial hypothalamus. In this study, we determined whether cardiovascular responses evoked from the paraventricular nucleus are also modulated by activation of central 5-hydroxytryptamine 1A receptors. In anesthetised rats, the increases in heart rate and renal sympathetic nerve activity evoked by bicuculline injection into the paraventricular nucleus were greatly reduced (by 54% and 61%, respectively), by intravenous administration of (±)-8-hydroxy-2-(di-n-propylamino)tetralin, an agonist of 5-hydroxytryptamine 1A receptors, but were then completely restored by subsequent administration of WAY-100635, a selective antagonist of 5-hydroxytryptamine 1A receptors.
INTRODUCTION
It is now well established that activation of serotonin type 1A (5-HT 1A ) receptors in the brain can modulate physiological and behavioural responses to a wide range of stressors. In particular, systemic administration of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, an agonist of 5-HT 1A receptors) has been shown to reduce, in a dose-dependent manner, the increases in heart rate and arterial blood pressure evoked by acute psychological stressors (33- 35, 48, 49) . Systemic administration of 8-OH-DPAT also reduces the cutaneous vasoconstriction evoked by physical stressors such as cold exposure or fever (34, 37, 38) . In several of these studies the effects of 8-OH-DPAT were shown to be selective for the 5-HT 1A receptors, because they were abolished by the selective 5-HT 1A receptor antagonist WAY-100635 (33, [35] [36] [37] [38] 49) .
In addition, the effects of 8-OH-DPAT can be attributed to a central action of the drug because it is known that systemically administered 8-OH-DPAT affects sympathetic activity by an action on the central nervous system (18,29).
Microinjection of 8-OH-DPAT into the medullary raphe reduces the tachycardia evoked by psychological stress or fever (33, 35) , and microinjection of WAY-100635 into this region reverses the inhibition of cold-evoked cutaneous vasoconstriction induced by systemic administration of 8-OH-DPAT (38) . Thus, the medullary raphe is one site at which 5-HT 1A receptors can suppress stress-evoked cardiac or cutaneous vasoconstrictor responses (33, 35, 38) .
At the same time, activation of 5-HT 1A receptors located in higher brain regions, such as limbic regions, may also reduce stress-evoked cardiovascular responses via an anxiolytic effect rather than via a direct effect on brainstem cardiovascular neurons (49) .
Apart from the fact that they are inhibited by activation of central 5-HT 1A receptors, cardiovascular responses evoked by acute psychological stress, cold exposure or fever are also all mediated to a significant extent by neurons within the dorsomedial hypothalamus (DMH) (9) (10) (11) 32) . Furthermore, the cardiovascular responses evoked by disinhibition of neurons in the DMH of anesthetised rats are also powerfully inhibited by systemic administration of 8-OH-R-00144-2011 revised -4 -DPAT, and these effects are also completely reversed by subsequent administration of WAY-100635 (24) . This raises the question as to whether cardiovascular responses mediated by brain regions that are independent of the DMH are also modulated by activation of central receptors. In particular, the hypothalamic paraventricular nucleus (PVN) contains neurons that regulate the sympathetic outflow via descending pathways that do not include synapses in the DMH (e.g. direct projections to sympathetic preganglionic neurons and an indirect projection via sympathetic premotor neurons in the rostral ventrolateral medulla) (7, 44, 46) . The PVN has long been known to have a crucial role in cardiovascular regulation, particularly in regard to the maintenance of fluid balance (6, 14) . The PVN may also be involved in the long-term regulation of sympathetic activity and blood pressure (8) and there is now considerable evidence that it contributes to the sustained activation of renal and cardiac sympathetic activity that occurs in heart failure and neurogenic hypertension (1, 4, 14, 40) . It has been proposed that the PVN is a potential target for treatment of sympathetic dysfunction in these conditions (14) , and so it is important to identify the mechanisms that modify the regulation of sympathetic activity by the PVN. The aim of this study was to test whether activation of 5-HT 1A receptors can modify the regulation of arterial pressure, heart rate and renal sympathetic nerve activity by the PVN.
MATERIALS AND METHODS

General
Procedures. Experiments were performed using male Sprague-Dawley rats (body weight 370-480 g) supplied by University of Sydney Laboratory Animal Services. All experimental procedures were approved by the Animal Ethics Committee of the University of Sydney and were carried out in accordance with the Guidelines for Animal Experimentation of the National Health and Medical Research Council of Australia. Anesthesia was initially induced by inhalation of isoflurane (2-3% in oxygen-enriched air). A thermo-regulated heating pad was used to maintain body temperature in the range 37-38 ºC as measured via a rectal probe. Catheters R-00144-2011 revised -5 -were placed in a femoral artery and a femoral vein for the recording of pulsatile arterial pressure and drug injection, respectively. After the surgery, the isoflurane anesthesia was gradually withdrawn while being replaced by urethane (1.3g/kg iv with supplementary doses of 0.1 g/kg iv if required). The adequacy of anesthesia was verified by the absence of the corneal reflex and a withdrawal response to nociceptive stimulation of a hind paw. A tracheotomy was performed to maintain an unobstructed airway and the animals were allowed to breathe freely.
The rat was then mounted prone in a stereotaxic frame with the incisor bar at 19 mm below the interaural line. The dorsal surface of the cortex was exposed for approaching the PVN and DMH. The renal sympathetic nerve on the left side was isolated from surrounding connective tissue and its activity was recorded as described previously (16) . The signal from the electrodes was amplified, passed through a band pass filter (100-1000 Hz), and then rectified and integrated over successive 10 sec intervals. At the end of the experiments, the baseline noise level of renal sympathetic nerve activity (RSNA) was determined by application of 2% lignocaine to the proximal end of the nerve. The mean arterial pressure (MAP) and heart rate (HR) signals were derived from the pulsatile pressure signal via a low-pass filter and rate meter, respectively. All signals were recorded on a computer using a PowerLab system (AD Instruments).
Microinjections were made using a glass micropipette held in a micromanipulator at an angle of 28º (tip caudal). The compound injected was bicuculline methochloride (Tocris, 20 pmol or 10 pmol in 20 nl). The vehicle solution was artificial cerebrospinal fluid adjusted to pH 7.4 and the drug solution contained 1% fluorescent microspheres to allow later histological determination of the injection sites. The tip of the micropipette was positioned stereotaxically (1.8 mm caudal to the bregma, 0.5-0.6 mm lateral to the midline, and 7.5-7.6 mm from the surface of the cortex).
In some experiments, the tip of the micropipettes was positioned in the DMH (3.1 mm caudal to bregma, 0.5-0.6 mm lateral to the midline, and 8.5-8.6 mm ventral to the surface of the cortex) or at a site in between the PVN and DMH (2.5 mm caudal to bregma, 0.5-0.6 mm lateral to the midline, and 7.5-7.6 mm ventral to the surface of the cortex). Microinjections were made R-00144-2011 revised -6 -by pressure, and the volume injected was measured by the displacement of the meniscus in the pipette with respect to a horizontal grid viewed through an operating microscope.
Experimental procedures. In 6 rats, an initial microinjection of bicuculline (20 pmol in 20 nl) was made into the PVN. After a waiting period of 30-50 min, to allow for all cardiovascular variables to stabilize again, the selective 5-HT 1A receptor agonist 8-OH-DPAT ((±)-8-hydroxy-2-(di-n-propylamino)tetralin, Tocris) was administered (100 µg/kg iv). After a further 5-10 min, a second microinjection of bicuculline was made into the same PVN site, and there was then a further waiting period of 30-50 min. The selective 5-HT 1A receptor antagonist WAY-100635 (Sigma) was then administered (100 µg/kg iv), after which there was a further waiting time of 5-10 min followed by a third and final microinjection of bicuculline into the same site in the PVN.
In a second series of experiments in 8 rats the effects of WAY-100635 alone on the responses was also tested. In these experiments, a microinjection of bicuculline (either 20 pmol (n=4) or 10 pmol (n=4)) was first made into the PVN. After a waiting time of 30-60 min, WAY-100635 was administered (100 µg/kg iv), after which there was a further waiting time of 5-10 min followed by a second microinjection of bicuculline into the same site in the PVN.
In a third series of experiments in 7 rats the effect of blockade of 5-HT 1A receptors within the PVN itself on the responses evoked by microinjection of bicuculline into the PVN was also tested. In these experiments the procedure was the same as in the first series of experiments, except that instead of a systemic injection of 8-OH-DPAT, a microinjection of 8-OH-DPAT (1 nmol in 100 nl solution) was made at the same co-ordinates in the PVN as the site at which bicuculline was injected. their respective pre-injection baseline levels were determined following each microinjection of bicuculline. One-factor ANOVA was used to compare the bicuculline-evoked peak changes in MAP, HR and RSNA before and after 8-OH-DPAT administration, and after subsequent WAY-100635 administration, followed by paired comparisons using the t-test with application of the Holm step-down procedure for multiple comparisons as appropriate (45) . Table 1 ). The RSNA initially increased rapidly after 8-OH-DPAT injection, but then declined to reach a new stable level by 5-10 min after the injection ( Fig. 1) , that was slightly but not significantly increased (by 18 ± 9%, P > 0.1) compared to its initial resting value ( Table 1 ).
RESULTS
Effects of 8-OH-DPAT and WAY-
The initial rapid increase in RSNA after injection of 8-OH-DPAT followed the initial decrease in MAP by approximately 2-3 sec, and thus may have been a baroreflex response to the decrease in MAP. After subsequent intravenous injection of WAY-100635 the MAP decreased transiently but then increased to reach a new stable level within 5-10 min that was slightly greater than the initial resting level (Fig. 1 , Table 1 ). The HR also increased after injection of WAY-100635 to reach a new stable level that was similar to the initial resting level (Fig. 1 , Table 1 ). In contrast, the RSNA initially increased transiently, then decreased, and then increased again more gradually to reach a level that was not significantly different from the initial resting level (Fig. 1 , Table 1 ).
Again, the initial transient changes in RSNA after injection of WAY-100635 followed the changes in MAP, but in the opposite direction, and so may have been a baroreflex response to the changes in MAP.
In the experiments in which WAY-100635 was injected intravenously, without prior injection of 8-OH-DPAT, WAY-100635 injection had no significant effect on the resting levels of
Effects of 8-OH-DPAT and WAY-100635 on bicuculline-evoked responses from the PVN.
In this series of experiments (n=6) microinjections of bicuculline into the PVN evoked a large increase in HR and integrated RSNA and a modest increase in MAP (Fig. 1) . The pattern of RSNA also changed, such that the amplitude of bursts increased, with periods of low activity between bursts (e.g. Fig. 1B ). This was particularly exaggerated in one experiment, in which the periods of inactivity in between intense bursts of RSNA were up to 1 sec in duration (Fig. 2 ).
This pattern of evoked RSNA in response to bicuculline microinjection into the PVN has been previously reported (26). The extreme bursting pattern of RSNA in this experiment resulted in a time course of integrated RSNA that was highly irregular ( 
After intravenous injection of 8-OH-DPAT, the maximum evoked increases in HR and
RSNA were greatly reduced ( Fig. 1 ) by 54 ± 6% (P = 0.0005) and 61 ± 7% (P = 0.0008), respectively. The evoked maximum increase in MAP was also decreased (by 55 ± 18%) but this did not reach statistical significance (P = 0.056). After subsequent intravenous injection of WAY-100635, the evoked maximum increases in MAP, HR and RSNA recovered back to levels that were not significantly different from their respective control responses (P = 0.25 to 0.77) ( Apart from reducing the magnitude of the evoked RSNA response, administration of 8-OH-DPAT also largely restored the normal pattern of RSNA (e.g. Fig. 2B ). After subsequent administration of WAY-100635, however, the bicuculline-evoked pattern of RSNA was very similar to that seen in the control response before 8-OH-DPAT administration, i.e. was characterized by high-amplitude irregular bursts (e.g. Fig. 2B ).
Effects of WAY-100635 alone on bicuculline-evoked responses from the PVN. In this series
of 8 experiments, we tested the effects of intravenous injection of WAY-100635, without prior injection of 8-OH-DPAT, on the responses evoked by microinjections of either 20 pmol (n=4) or 10 pmol (n=4) of bicuculline into the PVN. Two different doses of bicuculline were used, in case the higher dose evoked a maximal response, and thus masked any facilitatory effect of WAY-100635 on the response. As shown in Fig. 4 , however, although the magnitudes of the bicuculline-evoked increases in MAP, HR and RSNA were dose-dependent, they were not significantly changed after WAY-100635 injection (P = 0.41-0.98). As in the first series of experiments, bicuculline microinjection into the PVN evoked a pattern of RSNA characterized by high amplitude bursts separated by periods of low activity, and this response pattern was also not altered after WAY-100635 administration (Fig. 4C) .
Effects of 8-OH-DPAT in the PVN on bicuculline-evoked responses from the PVN.
In this series of 6 experiments, we tested the effects of microinjection of 8-OH-DPAT (1 nmol in 100 nl) into the PVN on the response evoked by bicuculline microinjection (20 pmol) into the same site in the PVN (Fig. 5) . Although the average bicuculline-evoked increases in MAP, HR and RSNA after 8-OH-DPAT microinjection tended to be reduced compared to the control responses and the responses evoked after subsequent intravenous injection of WAY-100635 ( (Fig. 6) .
Similarly, the increase in MAP evoked from the intermediate site was much less than that evoked from either the PVN or DMH, although the evoked HR response was not significantly different from that evoked from either the PVN or DMH (Fig. 6 ). (35, 49) . This dose was also the same as that which in our previous study (24) powerfully suppressed DMH-evoked cardiovascular responses. It is higher, however, than the mean effective dose (ED 50 ) for this compound, which has been estimated as close to 13.1 µg/kg (36) . This raises the question as to whether the dose used may have resulted in desensitization of the 5-HT 1A receptors. If that were the case, then the restoration of the bicuculline-evoked responses after WAY-100635 administration could be due simply to the absence of activation of 8-OH-DPAT on 5-HT 1A receptors rather than a reversal of that activation. This seems unlikely, however, because intravenous injection of WAY-100635 reversed the effects of 8-OH-DPAT on resting MAP and HR, but had no effect on MAP and only a small effect on resting HR when injected without prior administration of 8-OH-DPAT ( Table 1 ).
The compound 8-OH-DPAT has significant affinity for 5-HT 7 We have previously shown that systemic injection of the same dose of 8-OH-DPAT as used in the present study did not affect the reflex sympathoexcitatory response to chemoreceptor R-00144-2011 revised -14 -stimulation or the sympathoinhibitory response to baroreceptor stimulation (24). Furthermore, Vianna and Carrive (49) showed that systemic injections of 8-OH-DPAT, even at a higher dose (250 µg/kg) than that used in the present study, did not reduce the pressor and tachycardic response to cold exposure in conscious rats. Therefore the 5-HT 1A receptor-mediated inhibition of the PVN-evoked sympathoexcitation is not simply due to a non-specific inhibition of sympathetic reactivity. 
Effects of activation of 5HT
Possible location of site(s) at which 5HT 1A receptors suppress the PVN-evoked responses.
Since blockade of GABA receptors on PVN neurons evokes a cardiovascular response, the neurons that drive that response must receive tonic excitatory as well as tonic inhibitory inputs. 
Perspectives
The PVN has long been known to be a key brain region regulating the autonomic outflow, via direct and indirect connections to sympathetic and vagal preganglionic neurons (46) . It also receives multiple inputs from many other nuclei in the hypothalamus (e.g. subfornical organ, median preoptic nucleus, suprachiasmatic nucleus) and brainstem (e.g. periaqueductal gray, lateral parabrachial nucleus, tractus solitarius, ventrolateral medulla), which in turn relay signals from a variety of peripheral receptors (e.g. baroreceptors, cardiopulmonary receptors, chemoreceptors, osmoreceptors) as well as inputs that respond to changes in the levels of circulating hormones such as angiotensin II (14, 39) . There is also now much evidence that the PVN has an essential role in generating the sustained activation of renal and cardiac sympathetic activity that occurs in heart failure and neurogenic hypertension (1, 4, 14, 39, 40) . The present study demonstrates clearly that sympathoexcitatory responses generated by activation of PVN R-00144-2011 revised -18 -neurons can be powerfully inhibited by activation of 5-HT 1A receptors, raising the possibility that this may be a potential therapeutic tool for reducing the sympathoactivation that occurs in some forms of hypertension and heart failure (13, 40) . Future studies will be required to determine the precise sites at which activation of 5-HT 1A receptors reduces sympathetic activation evoked from the PVN, as well as the precise mechanisms of this effect.
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